Katherine Welles / Shutterstock.com
Bristol-Myers Squibb (BMS) and BioMotiv, a drug development accelerator, have launched Anteros Pharmaceuticals, a biotech focused on developing a new class of drugs for fibrotic and other inflammatory diseases.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
BMS, Bristol-Myers Squibb, BioMotiv, Anteros Pharmaceuticals, drug development, biotech, research and development, inflammatory diseases